Zobrazeno 1 - 10
of 26
pro vyhledávání: '"O N Anoshenkova"'
Autor:
I A Baranova, O B Ershova, E Kh Anaev, T N Anikhina, O N Anoshenkova, S Z Batyn, E A Belyaeva, T Yu Bolshakova, I A Volkorezov, L N Eliseeva, E V Kashnazarova, M F Kinyaykin, M N Kirpikova, E P Klyuchnikova, M A Korolev, I V Kuneevskaya, L V Masneva, A A Muradyants, E N Otteva, T N Petrachkova, L K Peshekhonova, A S Povzun, T A Raskin, M L Smirnova, N V Toportsova, R B Khasanova, N G Shamsutdinova, N L Shaporova, N S Shitova, S Yu Shkireeva, N A Shostak, O M Lesnyak
Publikováno v:
Остеопороз и остеопатии, Vol 17, Iss 3, Pp 9-14 (2014)
Objectives. This study is a part of GLUKOST study hosted and organized by the Russian Association of Osteoporosis. The aim was to estimate the incidence and risk factors of fractures in patients with chronic inflammatory diseases. Materials and Metho
Externí odkaz:
https://doaj.org/article/8d85a0c589f14cc5bab5a4f37b593b19
Publikováno v:
Научно-практическая ревматология, Vol 43, Iss 3 (2005)
Externí odkaz:
https://doaj.org/article/3b06da40108f44b9a7e70fd5241170db
Autor:
E. Y. Pogozheva, V. N. Amirjanova, T. Yu. Grineva, A. A. Baranov, A. M. Lila, E. L. Nasonov, N. Lapkina, R. R. Samigullina, Vadim I. Mazurov, O. N. Anoshenkova, A. E. Karateev
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 5, Pp 571-577 (2021)
Upadacitinib (UPA), a JAK inhibitor, is a new therapeutic option that allows patients with insufficient response to therapy with basic anti-inflammatory drugs (DMARDs) or genetically engineered biological drugs (GEBDs) to achieve the goals of therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b21c28a6c6be074c1f967446a44cd7
https://rsp.mediar-press.net/rsp/article/view/3077
https://rsp.mediar-press.net/rsp/article/view/3077
Autor:
L. M. Kudelya, E. V. Zonova, A. B. Opongosheva, S. A. Terpigorev, L. I. Alekseeva, Yu. P. Chasovskikh, A. V. Teteneva, T. V. Raskina, N. V. Yudina, O. N. Anoshenkova, T. V. Kropotina, D. N. Orlov, N. G. Ganyukova, N. M. Babadaeva, A. A. Kondrashov
Publikováno v:
Bûlleten' Sibirskoj Mediciny, Vol 19, Iss 3, Pp 113-119 (2020)
The aim of the study was to develop ways to improve the diagnosis and treatment of systemic sclerosis (SSc)-ILD. Interstitial lung disease (ILD) is a common manifestation of SSc. In the territory of the Siberian Federal District (SFD), the number of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47494716448a4b5637f1ce130debbf63
https://doi.org/10.20538/1682-0363-2020-3-113-119
https://doi.org/10.20538/1682-0363-2020-3-113-119
Autor:
A. S. Avdeeva, A. S. Misiyuk, A. M. Satybaldyev, G. V. Lukina, V. N. Sorotskaya, E. V. Zhilyaev, A. R. Babaeva, A. A. Baranov, V. I. Mazurov, I. N. Shendrygin, T. S. Salnikova, L. A. Knyazeva, D. G. Krechikova, R. R. Samigullina, I. Z. Gaidukova, D. I. Abdulganieva, I. N. Kushnir, O. N. Anoshenkova, N. A. Lapkina, E. A. Koshkarova, A. M. Lila, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 3, Pp 262-267 (2020)
Objective: to analyze the results of tofacitinib (TOFA) therapy in real clinical practice according to the All-Russian Arthritis Registry (OREL). Subjects and methods. The OREL Registry included 347 patients (286 (82%) women and 61 (18%) men) with rh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de5b3f28958f400c7855f9b3bba76be
https://doi.org/10.14412/1995-4484-2020-262-267
https://doi.org/10.14412/1995-4484-2020-262-267
Autor:
O. M. Lesnyak, E. N. Gladkova, O. B. Ershova, I. A. Skripnikova, O. N. Anoshenkova, Yu. R. Akhverdyan, K. Yu. Belova, I. B. Belousova, E. V. Bolshakova, A. V. Dreval, B. V. Zavodovsky, M. V. Ilyin, O. V. Kosmatova, L. V. Kryukova, A. A. Latfullin, E. A. Leikauskene, N. V. Leonova, Yu. V. Maksimova, M. A. Myagkova, V. E. Novikov, A. R. Nuriev, E. Yu. Polyakova, Yu. V. Polyakova, L. E. Sivordova, V. A. Tavluev, L. R. Shavalieva
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 6, Pp 626-635 (2019)
Objective: to analyze the clinical and organizational feasibility of using different intervention thresholds for the Russian population. Subjects and methods . The probability of fractures using the Russian FRAX model was calculated on a sample of 3,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c196e8a8cb97399daef584d5eaa099
https://doi.org/10.14412/1995-4484-2019-626-635
https://doi.org/10.14412/1995-4484-2019-626-635
Autor:
V. N. Amirdzhanova, E. Yu. Pogozheva, A. E. Karateev, O. V. Antipova, I. B. Vinogradova, A. Yu. Kazankova, R. G. Mukhina, A. G. Vasilyev, O. B. Nesmeyanova, E. A. Bogdanova, R. R. Samigullina, A. A. Vasilenko, I. B. Bashkova, T. S. Salnikova, I. N. Dashkov, N. E. Nikulenkova, V. Yu. Manokhin, I. P. Afanasyeva, O. N. Anoshenkova, T. V. Plaksina, M. R. Spitsina, L. V. Solodovnikova, A. V. Petrov, O. P. Slyusar, E. V. Papichev, E. V. Ivanova, L. V. Masneva, L. P. Evstigneeva, I. V. Kolotilina, E. N. Otteva, I. A. Cherentsova, I. N. Shchendrygin, S. A. Derevenskikh, I. G. Bannikova, N. K. Delyavskaya, I. N. Danilova, I. M. Marusenko
Publikováno v:
Современная ревматология, Vol 13, Iss 3, Pp 30-38 (2019)
Objective : to assess quality-of-life (QoL) dynamics in patients with rheumatoid arthritis (RA) when initiating therapy with biological agents (BAs) in real clinical practice. Patients and methods . The investigation enrolled patients with RA from th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1a7c3074886b6b8dfa1255eb6374b8
https://mrj.ima-press.net/mrj/article/view/929
https://mrj.ima-press.net/mrj/article/view/929
Autor:
O. N. Anoshenkova, A. N. Kalyagin, Yu. V. Maksimova, N. G. Sindykheeva, A. V. Sinkov, G. M. Sinkova
Publikováno v:
Современная ревматология, Vol 12, Iss 4, Pp 112-117 (2018)
Management of patients with knee osteoarthritis (OA) in the presence of comorbidity causes significant difficulties associated with the limitations of pharmacotherapy. Objective: to evaluate the clinical efficacy of ultraphonophoresis with a hyaluron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6fa4fef0aa428c0ee092e2164772cdd
https://mrj.ima-press.net/mrj/article/view/871
https://mrj.ima-press.net/mrj/article/view/871
Publikováno v:
Naučno-Praktičeskaâ Revmatologiâ, Vol 54, Iss 5, Pp 601-606 (2016)
Научно-практическая ревматология, Vol 54, Iss 5, Pp 601-606 (2016)
Научно-практическая ревматология, Vol 54, Iss 5, Pp 601-606 (2016)
The paper discusses the possibilities of administering hyaluronic acid in osteoarthritis. It is noted that the therapeutic efficacy of this drug class has been demonstrated in experimental and clinical studies and confirmed by the practical activitie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d68e5520ac2a10bd68b93e9b41a4d25
https://rsp.ima-press.net/rsp/article/view/2310
https://rsp.ima-press.net/rsp/article/view/2310
Autor:
R. M. Balabanova, T. V. Dubinina, D. V. Goryachev, O. N. Anoshenkova, E. A. Antonova, I. Yu. Ilyevsky, O. V. Semagina, N. V. Yasyukevih
Publikováno v:
Современная ревматология, Vol 9, Iss 2, Pp 33-36 (2015)
Methotrexate or leflunomide is used as a first-line synthetic disease-modifying anti-rheumatic drug in the therapy of rheumatoid arthritis (RA). In 2011, the Russian Federation registered and since it has been successfully using leflunomide**. Object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c4c84a302e5f229af6adb8b6f821e71
https://doi.org/10.14412/1996-7012-2015-2-33-36
https://doi.org/10.14412/1996-7012-2015-2-33-36